Kim J, Harper A, McCormack V, Sung H, Houssami N, Morgan E, Mutebi M, Garvey G, Soerjomataram I, Fidler-Benaoudia MM (2025) Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med 31(4):1154–1162. https://doi.org/10.1038/s41591-025-03502-3

Article  CAS  PubMed  Google Scholar 

Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025) Cancer statistics, 2025. Ca 75(1):10–45. https://doi.org/10.3322/caac.21871

Article  PubMed  PubMed Central  Google Scholar 

Xiong X, Zheng L-W, Ding Y, Chen Y-F, Cai Y-W, Wang L-P, Huang L, Liu C-C, Shao Z-M, Yu K-D (2025) Breast cancer: pathogenesis and treatments. Signal Transduct Target Ther 10:49. https://doi.org/10.1038/s41392-024-02108-4

Article  PubMed  PubMed Central  Google Scholar 

Wu G-Y, Xiao M-Z, Hao W-C, Yang Z-S, Liu X-R, Xu D-S, Peng Z-X, Zhang L-Y (2025) Drug resistance in breast cancer: mechanisms and strategies for management. Drug Resist Updat 83:101288. https://doi.org/10.1016/j.drup.2025.101288

Article  CAS  PubMed  Google Scholar 

Wang R, Hu B, Pan Z, Mo C, Zhao X, Liu G, Hou P, Cui Q, Xu Z, Wang W, Yu Z, Zhao L, He M, Wang Y, Fu C, Wei M, Yu L (2025) Antibody-Drug conjugates (ADCs): current and future biopharmaceuticals. J Hematol Oncol 18(1):51. https://doi.org/10.1186/s13045-025-01704-3

Article  PubMed  PubMed Central  Google Scholar 

Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A (2023) Antibody–drug conjugates come of age in oncology. Nat Rev Drug Discov 22(8):641–661. https://doi.org/10.1038/s41573-023-00709-2

Article  CAS  PubMed  Google Scholar 

Colombo R, Tarantino P, Rich JR, LoRusso PM, de Vries EGE (2024) The journey of antibody-drug conjugates: lessons learned from 40 years of development. Cancer Discov 14(11):2089–2108. https://doi.org/10.1158/2159-8290.Cd-24-0708

Article  CAS  PubMed  Google Scholar 

Beck A, D’Atri V, Verhoev O, Alez-Martin L, Letissier L, Delobel A, Fleury-Souverain S, François Y-N, Cianférani S, Gahoual R, Guillarme D, Hernandez-Alba O (2025) New frontiers in ADC analysis: advances in chromatography, electrophoresis, and mass spectrometry. AAPS J 28(1):34. https://doi.org/10.1208/s12248-025-01169-9

Article  CAS  PubMed  Google Scholar 

Khoury R, Saleh K, Khalife N, Saleh M, Chahine C, Ibrahim R, Lecesne A (2023) Mechanisms of resistance to antibody-drug conjugates. Int J Mol Sci. https://doi.org/10.3390/ijms24119674

Article  PubMed  PubMed Central  Google Scholar 

Tolaney SM, Jiang Z, Zhang Q, Barroso-Sousa R, Park YH, Rimawi MF, Saura C, Schneeweiss A, Toi M, Chae YS, Kemal Y, Chaudhari M, Şendur MAN, Yamashita T, Casalnuovo M, Danso MA, Liu J, Shetty J, Herbolsheimer P, Loibl S (2025) Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive metastatic breast cancer. N Engl J Med 0(0). https://doi.org/10.1056/NEJMoa2508668

Shim H (2020) Bispecific antibodies and antibody–drug conjugates for cancer therapy: technological considerations. Biomolecules. https://doi.org/10.3390/biom10030360

Article  PubMed  PubMed Central  Google Scholar 

Li F, Emmerton KK, Jonas M, Zhang X, Miyamoto JB, Setter JR, Nicholas ND, Okeley NM, Lyon RP, Benjamin DR, Law C-L (2016) Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models. Cancer Res 76(9):2710–2719. https://doi.org/10.1158/0008-5472.CAN-15-1795

Article  CAS  PubMed  Google Scholar 

Brinkmann U, Kontermann RE (2021) Bispecific antibodies. Science 372(6545):916–917. https://doi.org/10.1126/science.abg1209

Article  CAS  PubMed  Google Scholar 

Klein C, Brinkmann U, Reichert JM, Kontermann RE (2024) The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov 23(4):301–319. https://doi.org/10.1038/s41573-024-00896-6

Article  CAS  PubMed  Google Scholar 

Birch JR, Racher AJ (2006) Antibody production. Adv Drug Deliv Rev 58(5–6):671–685. https://doi.org/10.1016/j.addr.2005.12.006

Article  CAS  PubMed  Google Scholar 

Uppal H, Doudement E, Mahapatra K, Darbonne WC, Bumbaca D, Shen BQ, Du X, Saad O, Bowles K, Olsen S, Lewis Phillips GD, Hartley D, Sliwkowski MX, Girish S, Dambach D, Ramakrishnan V (2015) Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1). Clin Cancer Res 21(1):123–133. https://doi.org/10.1158/1078-0432.Ccr-14-2093

Article  CAS  PubMed  Google Scholar 

Labrijn AF, Janmaat ML, Reichert JM, Parren P (2019) Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov 18(8):585–608. https://doi.org/10.1038/s41573-019-0028-1

Article  CAS  PubMed  Google Scholar 

Han J, Xu K, Yang L, Ding Y, Wang X, Yin D, Wang J, Zhang H, Hong Z (2025) Cleavable pegylation enhances the antitumor efficacy of small-sized antibody–drug conjugates. Mol Pharm 22(6):3151–3163. https://doi.org/10.1021/acs.molpharmaceut.5c00090

Article  CAS  PubMed  Google Scholar 

Liu Z, Chen X (2016) Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy. Chem Soc Rev 45(5):1432–1456. https://doi.org/10.1039/c5cs00158g

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hoffmann RM, Coumbe BGT, Josephs DH, Mele S, Ilieva KM, Cheung A, Tutt AN, Spicer JF, Thurston DE, Crescioli S, Karagiannis SN (2018) Antibody structure and engineering considerations for the design and function of antibody drug conjugates (ADCs). Oncoimmunology 7(3):e1395127. https://doi.org/10.1080/2162402x.2017.1395127

Article  CAS  PubMed  Google Scholar 

Chan KR, Ong EZ, Mok DZ, Ooi EE (2015) Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases. Expert Rev Anti Infect Ther 13(11):1351–1360. https://doi.org/10.1586/14787210.2015.1079127

Article  CAS  PubMed  PubMed Central  Google Scholar 

Borlak J, Länger F, Spanel R, Schöndorfer G, Dittrich C (2016) Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcγ receptors. Oncotarget 7(19):28059–28074. https://doi.org/10.18632/oncotarget.8574

Article  PubMed  PubMed Central  Google Scholar 

Hale G (2024) Living in LALA land? Forty years of attenuating Fc effector functions. Immunol Rev 328(1):422–437. https://doi.org/10.1111/imr.13379

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mazor Y, Oganesyan V, Yang C, Hansen A, Wang J, Liu H, Sachsenmeier K, Carlson M, Gadre DV, Borrok MJ, Yu XQ, Dall’Acqua W, Wu H, Chowdhury PS (2015) Improving target cell specificity using a novel monovalent bispecific IgG design. MAbs 7(2):377–389. https://doi.org/10.1080/19420862.2015.1007816

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alley SC, Okeley NM, Senter PD (2010) Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 14(4):529–537. https://doi.org/10.1016/j.cbpa.2010.06.170

Article  CAS  PubMed  Google Scholar 

Drago JZ, Modi S, Chandarlapaty S (2021) Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol 18(6):327–344. https://doi.org/10.1038/s41571-021-00470-8

Article  PubMed  PubMed Central  Google Scholar 

Su Z, Xiao D, Xie F, Liu L, Wang Y, Fan S, Zhou X, Li S (2021) Antibody–drug conjugates: recent advances in linker chemistry. Acta Pharm Sin B 11(12):3889–3907. https://doi.org/10.1016/j.apsb.2021.03.042

Article  CAS  PubMed  PubMed Central